Electroretinographic changes in the inner and outer retinal layers before and after intravenous chemotherapy for retinoblastoma.
Humans
Retinoblastoma
/ drug therapy
Electroretinography
/ methods
Retinal Neoplasms
/ drug therapy
Male
Female
Child, Preschool
Infant
Retina
/ physiopathology
Antineoplastic Combined Chemotherapy Protocols
Child
Vincristine
/ therapeutic use
Follow-Up Studies
Antineoplastic Agents
/ administration & dosage
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
11
10
2023
accepted:
12
04
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
ppublish
Résumé
To study the inner and outer retinal functions using a full-field electroretinogram (ERG) before and after intravenous chemotherapy (IVC) in children with retinoblastoma (RB). Of the 11 eyes, seven had RB and four were normal. All children were examined under anesthesia using a handheld ERG machine with a standard protocol - light-adapted single-flash ERG (fERG), photopic single-flash 3.0- and 30-Hz flickers, and photopic negative response (PhNR) amplitudes at 72 ms (P72). The amplitudes and peak times were compared before and after IVC. Post-chemotherapy tumor regressed in all seven eyes. Of the seven eyes, the fERG peak time (a-wave) was delayed in two eyes (29%), whereas the b-wave was delayed in six eyes (86%). The fERG amplitude height for a- and b-waves decreased in five eyes (71%) and six eyes (86%), respectively. In addition, photopic flicker 30-Hz b-wave peak time delayed in five eyes (71%), whereas the b-wave amplitude height decreased in six eyes (86%). Simultaneously, the P72 amplitude height decreased in six eyes (86%), whereas the P-ratio increased in all seven eyes (100%). In comparison, the ERG responses improved in three of the four contralateral normal eyes. Overall, the cone function improved in two eyes (29%), whereas cone bipolar cell and retinal ganglion cell (RGC) function improved in one eye (14%) each. Comparison of light-adapted ERG changes before and after IVC showed reduced amplitudes and delayed peak times for both a and b waveforms, as well as reduced PhNR amplitude attributable to bipolar and RGC injury.
Identifiants
pubmed: 39078961
doi: 10.4103/IJO.IJO_2722_23
pii: 02223307-202472080-00017
doi:
Substances chimiques
Vincristine
5J49Q6B70F
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1168-1174Informations de copyright
Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.
Références
Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol 2009;93:21–23.
Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1330–8.
Murphree AL, Villablanca JG, Deegan WF 3rd, Sato JK, Malogolowkin M, Fisher A, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348–1356.
Gallie BL, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114:1321–8.
Chung CY, Medina CA, Aziz HA, Singh AD. Retinoblastoma: Evidence for stage-based chemotherapy. Int Ophthalmol Clin 2015;55:63–75.
Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115:1398–404, 1404.e1391.
Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications. Br J Ophthalmol 2012;96:1078–83.
Chandra K, Raval V, Reddy PV, Kaliki S. Primary macular retinoblastoma: Clinical presentation and treatment outcomes. J Vitreoretin Dis 2022;6:367–73.
Russo I, Levy-Gabriel C, Dupont A, Lumbroso-Le Rouic L, Cassoux N, Desjardins L, et al. Prospective phase II study of children affected by bilateral intraocular retinoblastoma with macular involvement of both eyes or in the only preserved eye. Macular tumor control, eye preservation rate, and visual outcome. Pediatr Blood Cancer 2021;68:e28721. doi: 10.1002/pbc.28721.
El Hamichi S, Acon D, Kon Graversen V, Gold AS, Berrocal AM, Murray TG. Persistent retinal detachment in retinoblastoma: The challenges. J Ophthalmol 2020;2020:1486757. doi: 10.1155/2020/1486757.
Ghose N, Agarwal P, Palkonda VAR, Kaliki S. Retinoblastoma associated with total exudative retinal detachment: Treatment and outcomes. Retina (Philadelphia, Pa) 2023;43:808–14.
Raval V, Parulekar M, Singh AD. Emerging new therapeutics for retinoblastoma. Ocul Oncol Pathol 2022;8:149–55.
Francis JH, Brodie SE, Marr B, Zabor EC, Mondesire-Crump I, Abramson DH. Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: Four-year experience. Ophthalmology 2017;124:488–95.
Francis JH, Abramson DH, Gobin YP, Marr BP, Dunkel IJ, Riedel ER, et al. Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: Six year review. PloS One 2014;9:e84247. doi: 10.1371/journal.pone.0084247.
Bogan CM, Kaczmarek JV, Pierce JM, Chen SC, Boyd KL, Calcutt MW, et al. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: A preclinical and clinical study. Br J Ophthalmol 2022;106:288–96.
Daniels AB, Froehler MT, Nunnally AH, Pierce JM, Bozic I, Stone CA, et al. Rabbit model of intra-arterial chemotherapy toxicity demonstrates retinopathy and vasculopathy related to drug and dose, not procedure or approach. Invest Ophthalmol Vis Sci 2019;60:954–64.
Abramson DH, Daniels AB, Marr BP, Francis JH, Brodie SE, Dunkel IJ, et al. Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma. PloS One 2016;11:e0146582. doi: 10.1371/journal.pone.0146582.
Francis JH, Schaiquevich P, Buitrago E, Del Sole MJ, Zapata G, Croxatto JO, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: A preclinical and clinical study. Ophthalmology 2014;121:1810–7.
Bone RA, Landrum JT, Fernandez L, Tarsis SL. Analysis of the macular pigment by HPLC: Retinal distribution and age study. Invest Ophthalmol Vis Sci 1988;29:843–9.
Liasis A, Paez-Escamilla M, Gruszewski J, Singh AD, Nischal KK. Melphalan toxicity following treatment of retinoblastoma identified by pattern electroretinogram. Ophthalmic Genet 2023;44:385–88.
Preiser D, Lagrèze WA, Bach M, Poloschek CM. Photopic negative response versus pattern electroretinogram in early glaucoma. Invest Ophthalmol Vis Sci 2013;54:1182–91.
Brodie SE, Paulus YM, Patel M, Gobin YP, Dunkel IJ, Marr BP, et al. ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma. Br J Ophthalmol 2012;96:877–80.
Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The International classification of retinoblastoma predicts chemoreduction success. Ophthalmology 2006;113:2276–80.
Raval V, Bowen RC, Soto H, Singh A. Intravenous chemotherapy for retinoblastoma in the era of intravitreal chemotherapy: A systematic review. Ocul Oncol Pathol 2021;7:142–8.
Frishman L, Sustar M, Kremers J, McAnany JJ, Sarossy M, Tzekov R, et al. ISCEV extended protocol for the photopic negative response (PhNR) of the full-field electroretinogram. Doc Ophthalmol 2018;136:207–11.
Wu Z, Hadoux X, Hui F, Sarossy MG, Crowston JG. Photopic negative response obtained using a handheld electroretinogram device: Determining the optimal measure and repeatability. Transl Vis Sci Technol 2016;5:8.
Trick GL. PRRP abnormalities in glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 1986;27:1730–6.
Viswanathan S, Frishman LJ, Robson JG, Harwerth RS, Smith EL 3rd. The photopic negative response of the macaque electroretinogram: Reduction by experimental glaucoma. Invest Ophthalmol Vis Sci 1999;40:1124–36.
Ventura LM, Porciatti V, Ishida K, Feuer WJ, Parrish RK 2nd. Pattern electroretinogram abnormality and glaucoma. Ophthalmology 2005;112:10–9.
Daniels AB, Froehler MT, Pierce JM, Nunnally AH, Calcutt MW, Bridges TM, et al. Pharmacokinetics, tissue localization, toxicity, and treatment efficacy in the first small animal (rabbit) model of intra-arterial chemotherapy for retinoblastoma. Invest Ophthalmol Vis Sci 2018;59:446–54.
Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: Preliminary results. JAMA Ophthalmol 2014;132:319–25.
Westall CA, Panton CM, Levin AV. Time courses for maturation of electroretinogram responses from infancy to adulthood. Doc Ophthalmol 1998;96:355–79.
Abdelhakim AH, Francis JH, Marr BP, Gobin YP, Abramson DH, Brodie SE. Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function. Br J Ophthalmol 2017;101:623–8.
Hobby AE, Kozareva D, Yonova-Doing E, Hossain IT, Katta M, Huntjens B, et al. Effect of varying skin surface electrode position on electroretinogram responses recorded using a handheld stimulating and recording system. Doc Ophthalmol 2018;137:79–86.
Osigian CJ, Grace SF, Cavuoto KM, Feuer WJ, Tavakoli M, Saksiriwutto P, et al. Assessing nonsedated handheld cone flicker electroretingram as a screening test in pediatric patients: Comparison to sedated conventional cone flicker electroretinogram. J AAPOS 2019;23:34.e31-5.
Robanus-Maandag E, Dekker M, van der Valk M, et al. p107 is a suppressor of retinoblastoma development in pR b-deficient mice. Genes Dev 1998;12:1599–609.
Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res 1999;59(7 Suppl):1731s-5s.